Altre lingue Mabwell (Shanghai) Bioscience Co., Ltd.

Azioni

688062

CNE100005RD2

Prezzo di chiusura Shanghai S.E. Altri mercati azionari 00:00:00 16/05/2024			Variaz. 5gg	Var. 1 gen.
33,16 ^CNY	-1,37%		-4,77%	+1,44%

07/05	Mabwell annuncia che la FDA concede la designazione di farmaco orfano a 9MW2821	CI
29/04	Mabwell (Shanghai) Bioscience Co., Ltd. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Mabwell Announces FDA Grants Orphan Drug Designation to 9MW2821	07/05
Mabwell Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04
Mabwell Announces MAIWEIJIAN, First Approved Biosimilar of Denosumab in China	08/04
Mabwell Bioscience Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	08/04
Mabwell Shanghai Bioscience Unit Gets Nod in China for Denosumab as Bone Tumor Treatment	04/04
Mabwell Presents Clinical Study Data of the 9MW2821 for Patients with Cervical Cancer as Focused Plenary Oral Presentation At the Society of Gynecologic Oncology Annual Meeting	19/03
Mabwell Scraps Licensing Deal With Yangtze River Pharma	27/02
Mabwell Publishes Phase III Study Results of Denosumab Biosimilar in the International Top Journal of Jama Oncology	21/02
Mabwell Receives IND Approval from FDA for Novel B7-H3 ADC 7Mw3711	20/02
Mabwell Shanghai Bioscience Gets US FDA's Nod to Trial on Tumor Drug; Shares Jump 5%	19/02
Certain A-Shares of Mabwell Bioscience Co., Ltd. are subject to a Lock-Up Agreement Ending on 18-JAN-2024.	18/01
National Medical Products Administration Accepts Mabwell's 8MW0511 for Injection Accepted by NMPA	19/12
Mabwell Announces the Cde Approval of Novel Nectin-4 Targeting Adc for Phase III Clinical Trial	11/12
Mabwell Shanghai Bioscience Gets Nod to Trial Urothelial Cancer Drug	08/12
Mabwell Announces Latest Clinical Progress and Data to be Reported on ESMO 2023 of 2 Novel Drugs	23/10/23
Mabwell Bioscience Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	18/10/23
Mabwell Announces First Patient Dosed in Phase Ib/II Trial of its Novel Nectin-4 Targeting ADC in Combination with PD-1 Inhibitor	28/09/23
Mabwell Bioscience Co., Ltd.(XSSC:688062) added to S&P Global BMI Index	18/09/23
Mabwell Bioscience Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	28/08/23
Mabwell Bioscience Co., Ltd. Announces the U.S. FDA approval of 9MW3811 for IND	15/06/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Mabwell (Shanghai) Bioscience Co., Ltd.

Azioni

688062

CNE100005RD2

Altre lingue

Filtri